Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab

• Published in: Annals of allergy, asthma, & immunology Vol. 108; no. 2; pp. 123 - 124
• Main Authors: Puxeddu, Ilaria, MD, PhD, Giori, Lucia, MD, Rocchi, Valeria, MD, PhD, Bazzichi, Laura, MD, Bombardieri, Stefano, MD, Tavoni, Antonio, MD, Migliorini, Paola, MD, Del Corso, Isabella, MD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.02.2012; Elsevier
• Subjects: Adalimumab; Adult; Aged; Aged, 80 and over; Allergy and Immunology; Anaphylaxis - diagnosis; Anaphylaxis - drug therapy; Anaphylaxis - etiology; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Autoimmune Diseases - drug therapy; Biological and medical sciences; Dermatology; Drug Hypersensitivity - diagnosis; Drug Hypersensitivity - drug therapy; Drug Hypersensitivity - etiology; Etanercept; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Humans; Immunoglobulin E - immunology; Immunoglobulin G - adverse effects; Immunoglobulin G - therapeutic use; Infliximab; Italy; Male; Medical sciences; Middle Aged; Receptors, Tumor Necrosis Factor - therapeutic use; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Treatment Failure; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Urticaria - diagnosis; Urticaria - drug therapy; Urticaria - etiology; Young Adult; Italy; Immunopathology; Dermatology; Hypersensitivity; Cytokine; Monoclonal antibody; Anti-Tumor Necrosis Factor-alpha; Immunology; Treatment; Etanercept; Infliximab; Anticytokine; Antagonist; Fusion protein; Adalimumab; Tumor necrosis factor α
• ISSN: 1081-1206; 1534-4436
• DOI: 10.1016/j.anai.2011.11.004